Information Provided By: 
Fly News Breaks for September 20, 2017
BIIB
Sep 20, 2017 | 07:24 EDT
SunTrust analyst Yatin Suneja says that Biogen's MS business faces "increasing market headwinds" but "remains very lucrative" and is poised to grow around 5% "over the next few years." The analyst adds that its "solid balance sheet provides M&A flexibility," while its Alzheimer's drug could generate $5B-$10B of revenue, which would enable the stock to rise 50%+. Target $360. .
News For BIIB From the Last 2 Days
